Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments
Journal of Clinical Medicine · 21.08.2026 · 15 (16) · 6473
DOI: 10.3390/jcm15166473 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.08.2026. Verfasst von Ruobing Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background/Objectives: Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder caused by recurrent upper-airway collapse during sleep, leading to intermittent hypoxia, sleep fragmentation, and excessive daytime sleepiness. Although continuous positive airway pressure (CPAP) remains the first-line therapy, long-term adherence is often suboptimal, underscoring the need for more tolerable and flexible treatment options. This review aims to summarize the pathophysiological rationale for pharmacotherapy in OSA and to discuss recent developments in drug-based interventions.
Methods
We conducted a narrative review of the literature on pharmacological interventions for OSA, with a systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to 4 August 2026. We included randomised controlled trials, observational studies, meta-analyses, and mechanistic human or animal studies that reported relevant sleep and respiratory outcomes, and graded evidence according to the principles of GRADE framework.
Results
Several drug classes have shown promise: agents that increase upper-airway dilator muscle activity, respiratory stabilizers that reduce loop gain, medications that raise the arousal threshold, topical anti-inflammatory drugs for mucosal edema, and systemic metabolic modulators such as glucagon-like peptide-1 receptor agonists and dual incretin receptor agonists. Emerging strategies, including gene therapy directed at the hypoglossal motor system, are also under investigation at the preclinical stage. Moreover, combining pharmacotherapy with CPAP or other devices can produce synergistic benefits, enabling lower device pressures and enhanced patient comfort.
Conclusions
Pharmacotherapy for OSA is progressively moving from exploratory research towards targeted, phenotype-driven personalized treatment. Future studies should focus on robust patient phenotyping, multi-mechanistic combination regimens, and long-term clinical outcome evaluations to facilitate the integration of drug-based therapies into routine OSA management, particularly in specific subgroups such as those with COMISA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Institute of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Hubei Province Clinical Research Center for Deafness and Vertigo, Wuhan 430022, China.
- Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan 430022, China.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zhou, R., Yin, G., Zhu, Y., & Sun, Y. (2026). Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments. Journal of Clinical Medicine, 15(16), 6473. https://doi.org/10.3390/jcm15166473
Vancouver
Zhou R, Yin G, Zhu Y, Sun Y. Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments. Journal of Clinical Medicine. 2026;15(16):6473. doi:10.3390/jcm15166473
BibTeX
@article{Zhou2026,
author = {Zhou, Ruobing and Yin, Ge and Zhu, Yun and Sun, Yu},
title = {Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6473},
doi = {10.3390/jcm15166473}
}
EUVIMED